Literature DB >> 8271851

Cost comparison of immediate angioplasty versus thrombolysis followed by conservative therapy for acute myocardial infarction: a randomized prospective trial. Mayo Coronary Care Unit and Catheterization Laboratory Groups.

G S Reeder1, K R Bailey, B J Gersh, D R Holmes, J Christianson, R J Gibbons.   

Abstract

OBJECTIVE: Immediate angioplasty and thrombolysis followed by conservative therapy are treatment strategies for acute myocardial infarction. The objective of this study was to compare the costs of these two strategies during a 12-month period.
METHODS: Of 103 patients with acute myocardial infarction who sought medical assistance within 12 hours after onset of symptoms, 4 were excluded from analysis for various reasons, 51 received tissue plasminogen activator, and 48 underwent immediate angioplasty as the initial revascularization strategy. The main outcome determinants were direct monetary costs and indirect measures of costs, including duration of hospital stay and return to work.
RESULTS: No significant difference in monetary costs between the two initial treatment strategies could be demonstrated. A trend was noted toward a briefer hospital stay and fewer late in-hospital procedures for patients treated initially with immediate angioplasty. Other measures of indirect costs were not statistically different.
CONCLUSION: The hypothesis that thrombolysis followed by conservative therapy would be more cost-effective than immediate angioplasty in the treatment of patients with acute myocardial infarction could not be substantiated. The two strategies seem to have similar cost-effectiveness.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8271851     DOI: 10.1016/s0025-6196(12)61604-8

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  6 in total

Review 1.  The limited incorporation of economic analyses in clinical practice guidelines.

Authors:  Joel F Wallace; Scott R Weingarten; Chiun-Fang Chiou; James M Henning; Andriana A Hohlbauch; Margaret S Richards; Nicole S Herzog; Lior S Lewensztain; Joshua J Ofman
Journal:  J Gen Intern Med       Date:  2002-03       Impact factor: 5.128

2.  The use of pharmaceuticals in critical care. The importance of outcome prediction models.

Authors:  G D Clifton; K Blumenschein
Journal:  Pharmacoeconomics       Date:  1995-05       Impact factor: 4.981

3.  Can the published cost analysis data for delivery of an efficient primary angioplasty service be applied to the modern National Health Service?

Authors:  N Melikian; K Morgan; K J Beatt
Journal:  Heart       Date:  2005-10       Impact factor: 5.994

Review 4.  Abciximab. A pharmacoeconomic review of its use in percutaneous coronary revascularisation.

Authors:  C J Dunn; R H Foster
Journal:  Pharmacoeconomics       Date:  1999-12       Impact factor: 4.981

5.  Comparative effectiveness of ST-segment-elevation myocardial infarction regionalization strategies.

Authors:  Thomas W Concannon; David M Kent; Sharon-Lise Normand; Joseph P Newhouse; John L Griffith; Joshua Cohen; Joni R Beshansky; John B Wong; Thomas Aversano; Harry P Selker
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2010-07-27

6.  Primary percutaneous coronary intervention in the Isfahan province, Iran; A situation analysis and needs assessment.

Authors:  Ali Reza Khosravi; Mohamadhosein Hoseinabadi; Masoud Pourmoghaddas; Shahin Shirani; Navid Paydari; Mahmoud Sadeghi; Soheila Kanani; Mahnaz Jozan; Elham Khosravi
Journal:  ARYA Atheroscler       Date:  2013-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.